Blood-brain barrier permeable β-blockers linked to lower risk of Alzheimer's disease in hypertension.
Ontology highlight
ABSTRACT: Alzheimer's disease is a neurodegenerative disorder in which the pathological accumulation of amyloid-β and tau begins years before symptom onset. Emerging evidence suggests that β-blockers (β-adrenergic antagonists) increase brain clearance of these metabolites by enhancing CSF flow. Our objective was to determine whether β-blocker treatments that easily cross the blood-brain barrier reduce the risk of Alzheimer's disease compared to less permeable β-blockers. Data from the Danish national registers were used to identify a retrospective cohort of individuals with hypertension, and those treated with β-blockers were included in the analysis. People with indications for β-blocker use other than hypertension (e.g. heart failure) were only retained in a sensitivity analysis. β-blockers were d
SUBMITTER: Beaman EE
PROVIDER: S-EPMC9976965 | biostudies-literature | 2023 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA